Search research articles
Contact Us
Filters
Showing results (41-50 of 150) with videos related to
Page
of 15
Sort By:
Organic & Biomolecular Chemistry
|
May 18, 2016
Assessment of reagents for selenocysteine conjugation and the stability of selenocysteine adducts
Lee Pedzisa, Xiuling Li, Christoph Rader, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
October 25, 2002
Integrin alpha(v)beta3 targeted therapy for Kaposi's sarcoma with an in vitro evolved antibody
Christoph Rader, Mikhail Popkov, John A Neves, et al.
Biochemistry
|
March 23, 2021
An Engineered Arginine Residue of Unusual pH-Sensitive Reactivity Facilitates Site-Selective Antibody Conjugation
Napon Nilchan, James M Alburger, William R Roush, et al.
The Journal of Biological Chemistry
|
July 5, 2012
Chemically programmed bispecific antibodies that recruit and activate T cells
Huiting Cui, Joshua D Thomas, Terrence R Burke, et al.
Biochemistry
|
November 10, 2009
Molecularly defined antibody conjugation through a selenocysteine interface
Thomas Hofer, Lauren R Skeffington, Colby M Chapman, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 17, 2008
Application of a trifunctional reactive linker for the construction of antibody-drug hybrid conjugates
Joshua D Thomas, Thomas Hofer, Christoph Rader, et al.
Angewandte Chemie (International Ed. in English)
|
January 28, 2003
A chemical adaptor system designed to link a tumor-targeting device with a prodrug and an enzymatic trigger
Anna Gopin, Neta Pessah, Marina Shamis, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
August 23, 2008
An engineered selenocysteine defines a unique class of antibody derivatives
Thomas Hofer, Joshua D Thomas, Terrence R Burke, et al.
Current Opinion in Chemical Biology
|
February 24, 2026
DVD-IgG1 antibody-drug conjugates: Expanding the landscape of targeted cancer therapy
Alexander F Kiefer, Andrew D Steele, Christoph Rader, et al.
Mabs
|
April 26, 2012
Targeting malignant B cells with an immunotoxin against ROR1
Sivasubramanian Baskar, Adrian Wiestner, Wyndham H Wilson, et al.
Page
of 15
Search research articles
Search
Showing results (41-50 of 150) with videos related to
Sort By:
Page
of 15
Organic & Biomolecular Chemistry
|
May 18, 2016
Assessment of reagents for selenocysteine conjugation and the stability of selenocysteine adducts
Lee Pedzisa, Xiuling Li, Christoph Rader, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
October 25, 2002
Integrin alpha(v)beta3 targeted therapy for Kaposi's sarcoma with an in vitro evolved antibody
Christoph Rader, Mikhail Popkov, John A Neves, et al.
Biochemistry
|
March 23, 2021
An Engineered Arginine Residue of Unusual pH-Sensitive Reactivity Facilitates Site-Selective Antibody Conjugation
Napon Nilchan, James M Alburger, William R Roush, et al.
The Journal of Biological Chemistry
|
July 5, 2012
Chemically programmed bispecific antibodies that recruit and activate T cells
Huiting Cui, Joshua D Thomas, Terrence R Burke, et al.
Biochemistry
|
November 10, 2009
Molecularly defined antibody conjugation through a selenocysteine interface
Thomas Hofer, Lauren R Skeffington, Colby M Chapman, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 17, 2008
Application of a trifunctional reactive linker for the construction of antibody-drug hybrid conjugates
Joshua D Thomas, Thomas Hofer, Christoph Rader, et al.
Angewandte Chemie (International Ed. in English)
|
January 28, 2003
A chemical adaptor system designed to link a tumor-targeting device with a prodrug and an enzymatic trigger
Anna Gopin, Neta Pessah, Marina Shamis, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
August 23, 2008
An engineered selenocysteine defines a unique class of antibody derivatives
Thomas Hofer, Joshua D Thomas, Terrence R Burke, et al.
Current Opinion in Chemical Biology
|
February 24, 2026
DVD-IgG1 antibody-drug conjugates: Expanding the landscape of targeted cancer therapy
Alexander F Kiefer, Andrew D Steele, Christoph Rader, et al.
Mabs
|
April 26, 2012
Targeting malignant B cells with an immunotoxin against ROR1
Sivasubramanian Baskar, Adrian Wiestner, Wyndham H Wilson, et al.
Page
of 15